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Abstract: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a disorder of un-
known physiopathology with multisystemic repercussions, framed in ICD-11 under the heading
of neurology (8E49). There is no specific test to support its clinical diagnosis. Our objective is to
review the evidence in neuroimaging and dysautonomia evaluation in order to support the neu-
rological involvement and to find biomarkers serving to identify and/or monitor the pathology.
The symptoms typically appear acutely, although they can develop progressively over years; an
essential trait for diagnosis is “central” fatigue together with physical and/or mental exhaustion after
a small effort. Neuroimaging reveals various morphological, connectivity, metabolic, and functional
alterations of low specificity, which can serve to complement the neurological study of the patient.
The COMPASS-31 questionnaire is a useful tool to triage patients under suspect of dysautonomia, at
which point they may be redirected for deeper evaluation. Recently, alterations in heart rate variabil-
ity, the Valsalva maneuver, and the tilt table test, together with the presence of serum autoantibodies
against adrenergic, cholinergic, and serotonin receptors were shown in a subgroup of patients. This
approach provides a way to identify patient phenotypes. Broader studies are needed to establish the
level of sensitivity and specificity necessary for their validation. Neuroimaging contributes scarcely
to the diagnosis, and this depends on the identification of specific changes. On the other hand,
dysautonomia studies, carried out in specialized units, are highly promising in order to support the
diagnosis and to identify potential biomarkers. ME/CFS orients towards a functional pathology that
mainly involves the autonomic nervous system, although not exclusively.
Keywords: Myalgic Encephalomyelitis (ME); Chronic Fatigue Syndrome (CFS); neuroimaging;
dysautonomia
1. Introduction
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) refers to the evolu-
tion and presence of severe, debilitating, and idiopathic chronic fatigue for more than 6
months, and is associated with other minor criteria, such as sleep disturbances, cognitive
disorders, post-exertional discomfort, or pain [1].
The prevalence of chronic fatigue in developed countries is estimated to be around
20% [2], and 33% in Japan [3], with ME/CFS assuming only a small part.
Since 2008, Spain has had a consensus document for this syndrome, sponsored by the
Institute for Health Carlos III and the Spanish Society for Neurology (SEN). It refers to a
minimum of 0.1% [4] of the population affected by the syndrome, although the ranges are
highly dispersed (0.0052 to 6.40%) depending on authors and methodology [5].
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This pathology appears to be framed among neurological diseases in the International
Classification of Diseases (ICD-11: 8E49) [6], even though it has numerous multisystemic
repercussions. There is a medical debate about the nature of this entity. A survey conducted
by the Association of British Neurologists in the United Kingdom, the birthplace of Myalgic
Encephalomyelitis (ME), reported that 84% of the 351 neurologists surveyed indicated the
pathology cannot be considered in the usual “neurological” sense, despite knowing its
neurological classification [7].
ME/CFS affects both sexes, but more frequently women (4:1 ratio, women/men) [8,9],
at any age (between 11 and 69 years), and mostly those of Caucasian ethnicity [10,11]. Direct
and indirect costs are extremely high; in the United States alone, the cost was estimated to
be USD 18–24 billion [12].
It is a pathology for which an etiopathogenesis or pathophysiology that clarifies the
underlying mechanisms has not yet been established, referring to it as a neuro-immune-
endocrine dysfunction, with an exclusively clinical diagnosis [13].
The nomenclature, classification, and diagnostic criteria have undergone various
changes [14,15]. The most recent change took place in 2015 when the US National Academy
of Medicine proposed the name of Systemic Exertion Intolerance Disease [16], a hybrid
between the criteria for CFS (detailed by Fukuda, 1994) and ME (detailed by Carruthers,
2011), which does not solve the lack of definition of the syndrome.
ME/CFS presents features in common with other pathologies that lead to “central” fa-
tigue, exercise intolerance, cognitive alterations, and the need for prolonged rest. Infections,
muscle weakness, and the presence of dysautonomia symptoms can occur in Multiple
Sclerosis [17], Parkinson’s disease, and other neurodegenerative disorders, as well as in
non-psychotic major depression, a condition with which it can coexist with psychosomatic
disorders, which are not excluded by the Fukuda criterion, which is the most frequently
used criterion. Sometimes it is difficult to differentiate this process when symptoms are
combined. Likewise, it is crucial to find differential diagnoses with pathologies, such as the
Postural Orthostatic Tachycardia Syndrome (POTS).
Our aim is to present an updated vision of the changes that can be observed in ME/CFS
by neuroimaging and in the evaluation of dysautonomia in order to find indicators or
biomarkers that could serve to establish a suspected diagnosis, a positive identification,
and/or for the follow-up of its evolution.
2. Development
The symptoms typically appear acutely, although they can develop progressively over
years. The “central” fatigue together with physical and/or mental exhaustion after a small
effort, sometimes minimal, is an essential trait for diagnosis [18].
The mechanisms of “central” fatigue are still unknown, including the brain areas
where such information is processed. The fatigue is defined by “A sustained feeling of
tiredness, which is not directly related to physical activity, although that can worsen it
disproportionately, and additionally, does not improve with rest. Patients feel tired in the
morning and experience an inability to perform any activity, being responsible for physical
and cognitive weakness and appearing as the integration of emotions, volition, cognition
and motility” [19].
Therefore, “central” fatigue would be secondary to the interrelation of different exter-
nal and internal stimuli, involving cognitive, emotional, motor, and sensory factors [20].
In the genesis of this fatigue, areas from the prefrontal cortex and basal nuclei have been
involved, pointing to dopamine as a relevant neurotransmitter [21].
The existence of a “fatigue network” homologous to the “pain network” (neuromatrix)
is yet to be determined, but the circuits for executive functions (planning, sequencing,
anticipation, reasoning, flexibility, etc.) and cognitive control (attention, working memory,
and inhibition) [22] are postulated as potential biomarkers. In this sense, the hypothalamus
acquires a special relevance as a key organizer to understand the homeostatic energy
balance in those neurological diseases with “central” fatigue [23].
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Sleep patterns were altered, for instance, referring to a “non-restorative” sleep (patients
wake up too exhausted to perform daily activities). The mechanisms of this alteration have
not been clarified but point to disorders in chronobiology (sleep/wake rhythms), where
the retino-hypothalamic bundle, suprachiasmatic nucleus (hypothalamus), pineal gland,
brain stem, and their connections play an essential role in the adjustment of the biological
clock [24–26] and in understanding this neuro-metabolic disorder. Frequently, patients
refer to a state described as mental fog or “brain fog”, which is characterized by sluggish,
fuzzy, “not sharp” thinking.
The diagnostic criteria mostly used in the different studies are those enunciated by
Fukuda et al. [1]. These raise some definition problems. On the one hand, it leaves the door
open to various psychiatric pathologies, such as personality disorders or psychosomatic
ones. On the other hand, it excludes those patients who do not suffer from any type of
pain. The Fukuda criteria were branded as “ambiguous” in 2003 by Reeves et al. [27]. In
such a way, Carruthers et al. (2011) advised abandoning them and using their proposed
criteria as a result of a broader “international consensus” [18].
Another frequent deficit of many publications is the absence of a list for the comor-
bidities that usually accompany these patients (musculoskeletal, endocrine, autoimmune,
dysautonomia, etc.). It is not a minor point, rather it is of enormous relevance when it
comes to enabling the establishment of clinical subgroups. The US National Academy of
Medicine strongly recommends, in order to better address the syndrome, a characterization
of clinical phenotypes (CFS + autoimmune disease, CFS + Fibromyalgia, CFS + POTS,
CFS + anxiety) [16].
3. Neuroimaging
Neuroimaging techniques, mainly magnetic resonance imaging (MRI), allow for the
study of the morphology, metabolism (by spectroscopy), and anatomical (by tractography)
and functional connectivity (by BOLD signal) of the different brain areas. Advances in
MRI have allowed the growth of knowledge and enhanced interest of researchers in this
field. MRI is currently preponderant over other techniques. We must emphasize that we
are facing a functional pathology without evidence of a morpho-molecular substrate.
Studies of the brain volume using VBM (Voxel-based morphometry) show some
regional differences for both gray and white matter [28–30], but there are no significant
differences in respect to controls.
Studies of structural connectivity (tractography) using DTI (Diffusion tensor imaging)
reflect changes in the white matter, which may or may not be reversible, for example, in the
internal capsule or in the prefrontal area to compensate the dysfunction of the ascending
reticular pathways [31]. Using DTI, Zeineh et al. (2015) proposed the arcuate fascicle,
commonly involved in language functions and word learning, as a potential biomarker
for the diagnosis and monitoring of ME/CFS [32]. No other group has thus far reported
another study that corroborates or refutes this proposal.
Functional connectivity allows the mapping of synchronous and asynchronous ac-
tivation in different brain areas. For this issue, fluctuations of the BOLD (blood oxygen
level-dependent) signal are studied. BOLD is the more common technique used to explore
functional connectivity, although it can be also studied using the arterial spin labeling
(ASL) technique. Several authors [33–36] document variations in neural activity at rest and
after slight activity, either an increase or decrease, in brain areas involved in executive and
control functions, such as anterior and posterior cingulate cortex; insula; and posterior,
parietal, and prefrontal cortex. In order to model these regions in a comprehensive way,
Menon (2011) proposed an interaction model called “Triple network model”: DMN (default
mode network), CEN (central executive network), and SN (salience network) [37]. Thus,
it highlights the essential role of these regions and their interactions in the control of the
individual’s behavioral strategies (Figure 1). Studies of alterations in the synchronization
of neural networks reflect a marked hypoactivity in these patients. The analysis of electri-
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cal neuroimaging (eLORETA) helps to understand the dysfunctions associated with the
syndrome in cognitive areas [38–40].
Figure 1. Graphic illustration of the triple network model for cognitive control proposed by Menon composed of the
“Default Motor Network” (DMN), the “Salience Network” (SN), and the “Central Executive network” (CEN). According to
this model, the anterior insula (belonging to the executive network) plays a key role since it activates CEN and deactivates
DMN in response to outgoing stimuli to perform tasks of attention, planning, and working memory.
The study of cerebral perfusion using arterial spin labeling (ASL), a non-invasive
method that is also used with MRI, shows a decrease in regional cerebral perfusion. These
studies complement volumetry and connectivity (anatomical and functional, tractography,
and BOLD) [41–43].
The MR-spectroscopy performs a non-invasive analysis of different metabolites (N-
acetylaspartate (NAA), creatine (Cr), choline (Cho), myo-inositol (MI), glutamine (Gln),
glutamate (Glu), and lactate). Some authors report an intraventricular increase of lactate
among them, which may be a result of the anaerobic metabolism [44–46]. Lactate accumu-
lation may also appear in pathologies, such as fibromyalgia [47], non-psychotic depressive
syndrome [48], and pathologies that frequently overlap with ME/CFS. Lactate is linked
to mitochondrial metabolism. Several authors refer to the compromise of mitochondrial
function, finding alterations in oxidative metabolism with a decrease in glutathione [35,43].
Studies with MRI (7.0-Tesla) have reported an overactive metabolism with GABA
decrease in the anterior cingulate cortex and glutamate and glutamate + glutamine ele-
vation in the putamen [35]. The neuronal viability marker N. acetylaspartate (NAA) is
decreased (↓ NAA/Cr) in the prefrontal cortex, an area involved in the cognitive control.
The assessment of this ratio may be useful to understand cognitive dysfunctions and to
establish a subgroup of patients showing higher pain scores [49].
Neuroinflammation (encephalitis/myelitis) has been demonstrated with positron
tomography (PET) [50,51] but lacks the neuropathological correlate. Other publications
with this technique focus on the metabolism of serum acetylcholine (muscarinic) antibodies,
trying to establish the commitment of neurotransmitters and their receptors in cognitive
function, reaching the conclusion that they do not alter these functions [52].
Recently, MRI studies measuring cerebral perfusion indicated high resting cerebral
perfusion associated with greater severity of dizziness symptoms. This may correspond to
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alterations in the brain stem neurovascular regulation mechanisms to cope with changes in
blood pressure due to orthostatic stress [53,54].
The involvement of any of these brain stem regions (ascending reticular substance,
among others) could explain both cognitive dysfunction and the involvement of the auto-
nomic nervous system in the control of homeostatic mechanisms.
4. Dysautonomia
The autonomic dysfunction constitutes one of the most frequent features in ME/CFS [55].
Palpitations, orthostatic intolerance (hypotension, tachycardia), frequent need to urinate,
alterations in thermoregulation, etc., appear in 90% of patients with ME/CFS [56]. Some
authors consider the syndrome as a dysautonomic pathology [57], so much so that they
come to propose it as a biomarker of the disease [58,59]. Perhaps in the future, a change
in the nomenclature of the syndrome could be proposed as “idiopathic chronic dysauto-
nomic syndrome”.
Variables related to blood pressure (systolic pressure, diastolic volume, cardiac output,
heart rate, etc.) are clearly altered for many affected by ME/CFS compared to controls [60].
We can also find an inability to focus vision, hypersensitivity to light [61], noise, vibration,
smell, taste, and touch, as well as alterations in depth perception, muscle weakness, spasms,
poor coordination, a feeling of instability, and ataxia [18].
The COMPASS-31 is an abbreviated clinical questionnaire organized into six domains
to explore the autonomic nervous system (orthostatic intolerance, vasomotor, secretomotor,
pupillomotor, gastrointestinal transit, or bladder control). This questionnaire is a useful
tool for the triage of patients under suspect and can guide towards the need for a deeper
evaluation of the autonomic function (respiratory arrhythmia, Valsalva maneuver, tilt table
protocol, or others) [62] in a dysautonomia unit, highlighting its importance.
The sympathetic/parasympathetic imbalance has been referred to in several publi-
cations that highlight the predominance of sympathetic activity. It causes alterations in
heart rate variability (HRV) with an increase in the ratio (LF/HF), and provides a possi-
ble explanation of both physical and mental fatigue [63,64]. Delving into this imbalance
(sympathetic/parasympathetic), according to some authors it points to a dysfunction of
the autonomic nervous system with reduced nocturnal parasympathetic activity [65] and
an increase of sympathetic activity [66].
In the latest proposal for a terminological change in this pathology, the US National
Academy of Medicine advocates for the name of Systemic Exertion Intolerance Disease [16],
highlighting an important feature of the syndrome, the marked and rapid fatigability
together with a prolonged recovery time (at least 24 h). This aspect differs from the
“central” fatigue experienced by patients with pathologies, such as multiple sclerosis or
Parkinson’s disease. In them, rehabilitation including physical exercise is mandatory. It
is a pillar in the management of these diseases, being irrelevant to the presence of post-
exertional discomfort. In contrast, the “chronic status” of ME/CFS patients deteriorates or
worsens significantly if physical exercise is incorporated into their treatment [67–69].
The biological background of ME/CFS symptomatology involves molecules dis-
tributed throughout the body. All of them are regulators of essential functions in tissue
homeostasis, for instance receptors such as adrenergics [70], serotonin [71] or TRP (transient
receptor potential channels) [72].
The molecular and anatomical diversity among serotonin receptors means that the
serotonergic system is involved in the regulation of pain, inflammation, memory, sleep,
appetite, thermoregulation, and various neuroendocrine functions, as well as depression,
anxiety and chronic fatigue [73]; all or many of these symptoms are part of the syndrome
that concerns us.
In this sense, Yamamoto et al. (2004) [74] reported a decrease in the density of serotonin
transporter (5-HTTs) in anterior cingulate cortex and Cleare et al. (2005) [75] reported
a marked decrease in 5-HT1A receptors in the hippocampus, both by positron tomogra-
phy (PET). There are a considerable number of articles highlighting the essential role of
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neurotransmitters in ME/CFS [76], but they always offer small samples of patients and
inhomogeneous clinical criteria for identification.
Several studies provide evidence on the presence in serum of autoantibodies against
neurotransmitter receptors, such as acetylcholine [52,77], norepinephrine [70], and sero-
tonin [78], at least in a subgroup of patients. In this sense, some authors postulate that
we could be facing an autoimmune pathology [79], at least in some of its forms, opening
the possibility for a subgroup of patients (yet to be determined) to a treatment with im-
munomodulators or immunoadsorption [80]. However, recent publications did not find
an increase in the frequency of autoantibodies, such as NMDA (related to some autoim-
mune encephalitis) nor LRP4, ACHR, and MuSK (associated with myasthenia gravis) [81],
nor against the mitochondrial membrane [82]. Larger longitudinal studies are needed
to determine the role of much of these antibodies, since they also appear elevated in
control samples.
Neuroanatomical structures involved in the symptomatology of ME/CFS are multiple.
We are suggesting the hypothalamus (paraventricular nucleus) as the biological center of
the symptomatology. It triggers the stimulation of the hypothalamic–pituitary–adrenal
axis, receiving modulation from emotional processing regions, such as the prefrontal cortex,
the hippocampus, and the amygdala, via the bed nucleus of the stria terminalis (modulator
in dysregulation of mood, anxiety, and fear) [83].
Autonomic symptoms are dependent on the regulation of the paravertebral ganglia or
the celiac plexus. Constipation is related to the myenteric plexuses, nocturia, impotence,
or urination related to the pelvic plexus, dysesthesias, and pain depending on epidermal
innervation. Deficits of attention are related to the prefrontal cortex; sleep disorders
are related to the raphe nuclei and locus coeruleus, etc.; and emotional symptoms are
related to the amygdala or hippocampus; much of them point to fine fiber neuropathy as a
potential substrate [19].
This pathology has a cardiac, pulmonary, digestive, or bladder component, but it does
not seem to be primarily cardiological, pneumological, gastroenterological, or urological,
etc. However, it does reasonably allow us to think that it was originally a dysregulation of
the central, peripheral, and autonomic nervous systems; it goes without saying that one of
the central characteristics of the nervous system is to be highly integrated, coordinated, and
reciprocally modulated. It is a syndrome in which some symptoms are explained from the
neurology. Perhaps it is primarily or fundamentally a neurological disease, as it appears in
the international classification.
To advance our understanding of the syndrome in the coming decades, the nomencla-
ture and diagnostic criteria will have to be clarified, and a universal research methodology
based on relevant aspects must be established, thus debuting the syndrome (allowing mod-
eling the disease, post-viral and post-toxic, etc.), clinical phenotypes, the same evaluation
scales, and standardized questionnaires, etc. The collection of this evidence will allow for
the understanding of the role of the nervous system. In this sense, the EUROMENE Group
(The European Network on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome) has
made an effort for consensus [84,85].
5. Conclusions
The neurobiopathological substrate of ME/CFS is unknown. There currently is no
neuroimaging finding or specific laboratory test to establish the diagnosis. Changes
reported in volumetry, cerebral blood flow, anatomy, and functional connectivity, at rest as
well as in response to stimuli reveal the existence of brain dysfunctions, whose meaning
is yet to be determined. The interpretation of findings is complicated by the lack of a
consensual study protocol.
The available evidence on the involvement of the autonomic nervous system (sym-
pathetic/parasympathetic imbalance) indicates that the neurologist plays an essential
role in the clinical evaluation of the syndrome and highlights the potential benefits of
dysautonomia units for a better understanding of these dysfunctional pathologies.
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